TuHURA Biosciences, Inc.
NASDAQ:HURABiotechnology
+$0.14 today
- Market cap
- $87.31M
- Beta
- 0.01
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.52
Volume 0.19M
Average 0.85M
HURA Common Stock Issued
Cash raised by issuing new shares.
TuHURA Biosciences, Inc.NASDAQ: HURA
Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026
Common stock issued grows 174449.2% year over year
Q1 FY2026 common stock issued of $7.35M rose 174449.2% year over year. Sequentially, it rose 18.7% from the prior quarter. Over 3 fiscal years it compounded at +125.9% a year.
Context
- Common stock issued increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 21.92M USD
- Year-over-year change
- +338.5%
- 4-year CAGR
- +40.7%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 21.92M | +338.5% |
| FY2024 | 2024-12-31 | 5M | -52.7% |
| FY2023 | 2023-12-31 | 10.58M | +455.8% |
| FY2022 | 2022-12-31 | 1.9M | -66.0% |
| FY2021 | 2021-12-31 | 5.6M | — |
Common Stock Issued vs competitors
How HURA compares with its peers on the latest reported figures
- HURA's LTM Mar 2026 common stock issued of $22.86M is the 5th largest of the 9 companies compared; the peer median is $24.41M.
- Over three fiscal years its annual growth of +125.9% compares with a peer median of -21.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
IRDOpus Genetics, Inc. | LTM Mar 2026 | $56.66M | +577.7% | +123.1% | 472.9% |
| LTM Mar 2026 | $53.14M | +10.8% | -13.8% | — | |
| LTM Mar 2026 | $37.31M | +33.3% | -28.5% | 30.1% | |
| LTM Mar 2026 | $35.67M | +162.3% | +91.0% | — | |
| LTM Mar 2026 | $22.86M | — | +125.9% | — | |
| LTM Mar 2026 | $13.15M | +108.6% | -48.4% | 1146.1% | |
| LTM Mar 2026 | $449K | — | — | 3.0% | |
| LTM Mar 2026 | $147K | +210.5% | -78.3% | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding HURA) | $24.41M | +135.5% | -21.1% | 30.1% | |
Competitors are the stored peer set for HURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (7.02M) | (9.37M) | (29.32M) | (21.68M) | (30.05M) |
| Depreciation & Amortization | 380.69K | 373.09K | 177.38K | 116.71K | 71.27K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 654.53K | 218.28K | 478.89K | 1.96M | 6.42M |
| Change in Working Capital | (55K) | 1.56M | 486.92K | 3.29M | (3.15M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | (55K) | 1.56M | 486.92K | 3.29M | (3.15M) |
| Other Non-Cash Items | (527.06K) | (294.07K) | 21M | 1.59M | (924.51K) |
| Operating Cash Flow | (6.56M) | (7.51M) | (11.95M) | (14.73M) | (27.63M) |
| Capital Expenditures | (3.28K) | (232K) | (79.22K) | (57.91K) | (76.08K) |
| Acquisitions (Net) | 0 | 0 | (1.22M) | (5.99M) | (1.26M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (3.28K) | (36.28K) | (1.3M) | (6.05M) | (1.34M) |
| Debt Repayment | 294.07K | (350K) | 2.69M | 28.57M | 616.98K |
| Common Stock Issued | 5.6M | 1.9M | 10.58M | 5M | 21.92M |
| Common Stock Repurchased | 0 | 0 | (24.75K) | 0 | 0 |
| Dividends Paid | (8K) | (8K) | (6K) | 0 | (8.36K) |
| Other Financing Activities | 8K | 0 | 0 | (3.8M) | (2.61M) |
| Financing Cash Flow | 7.04M | 16.25M | 2.66M | 29.77M | 19.93M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 477.91K | 8.71M | (10.59M) | 8.99M | (9.04M) |
| Free Cash Flow | (6.57M) | (7.54M) | (12.03M) | (14.79M) | (27.71M) |
TuHURA Biosciences, Inc.
NASDAQ:HURA
Intrinsic Alpha fair value
Locked
Current Price
$1.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.